EUCTR2004-000411-25-IT进行中（未招募）不适用
A phase II trial and scheduling finding of cetuximab in combination with rapidly alternating chemo-radiation in unresectable,locally advanced, squamous cell carcinoma of the head and neck (HNC)
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST0 个研究点开始时间: 2005年9月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Open-label, phase II, multicentre study on cetuximab treatment asfirst-line monotherapy in elderly patients with metastatic colorectalcancer expressing EGFREpidermal Growth Factor Receptor-expressing in metatstatic colorrectal cancer in first line treatment.EUCTR2004-001696-19-ESSpanish Cooperative Group for Gastrointestinal Tomour therapy40
已完成
不适用
Phase II crinical trial of cetuximab rechallenge with KRAS wild-type unresectable/recurrent colorectal cancerColorectal cancerJPRN-UMIN000009698Okayama Molecular Target-Based Drugs Society for Cancer of the Colon and Rectum25
进行中（未招募）
不适用
Ensayo clínico fase II con cetuximab bisemanal en combinación con oxaliplatino, 5-fluorouracilo y ácido folínico (folfox-4) en el tratamiento de primera linea del cáncer colorectal metastásico kras tipo natural.EUCTR2008-006909-16-ESACROSS:Associació Catalana per a la Recerca Oncològica i les seves implicacions sanitàries i Socials
进行中（未招募）
不适用
Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategiesHistologically proven newly diagnosed unresectable squamous cellcarcinoma of the head and neckEUCTR2006-004189-14-HUEORTC50
已完成
2 期
Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategieshead and neck carcinomalaryngeal cancer10027655NL-OMON32191EORTC10